Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Thio

Anesthesiology Murrieta, CA Medical Doctor

NPI 1356310957 CMS profile 106291

41670 Ivy St, Suite B, Murrieta, CA 92562

Open in the dashboard

General payments

$26,392

677 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Thio of Murrieta, CA is reported in the CMS Open Payments database as having received $26,392 across 677 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,137 101
2024 General $6,052 93
2023 General $7,053 155
2022 General $3,115 113
2021 General $1,922 87
2020 General $1,303 94
2019 General $808 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Thio
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Andrew Thio were reported at $6,137. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Andrew Thio Anesthesiology median Middle half National median
2019 $808 $72 $23–$151 $163
2020 $1,303 $36 $17–$120 $114
2021 $1,922 $49 $21–$135 $132
2022 $3,115 $52 $22–$144 $149
2023 $7,053 $53 $23–$143 $160
2024 $6,052 $55 $25–$150 $164
2025 $6,137 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $22,879 522 payments
  2. Medtronic USA, Inc. $2,033 124 payments
  3. Nevro Corp. $632 14 payments
  4. Stimwave Technologies Incorporated $185 4 payments
  5. SI-BONE, Inc. $174 3 payments
  6. Abbott Laboratories $152 2 payments
  7. Boston Scientific Corporation $114 1 payment
  8. Curonix LLC $76 2 payments
  9. Vertos Medical, Inc. $67 1 payment
  10. Painteq LLC $35 1 payment
  11. Other $45 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $25,961 675 payments
  2. Education $431 2 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $19,824 417 payments
  2. INTELLIS Spinal Cord Neurostimulation $1,721 110 payments
  3. INTELLIS Spinal Cord Neurostimulation $1,555 80 payments
  4. VANTA ADAPTIVESTIM $884 11 payments
  5. Senza $583 12 payments
  6. Vanta $247 3 payments
  7. RESTORE $221 5 payments
  8. StimQ Freedom-8A Receiver Kit Channel A US w/ Receiver $185 4 payments
  9. StimQ Receiver Stimulator Kit Channel A US w/Receiver $185 4 payments
  10. Freedom-4A Receiver Kit Channel A US w/ Receiver $185 4 payments
  11. Other $1,296 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

260

Median for Pain Management: 951

Drug cost

$2,949

Median for Pain Management: $26,034

Branded share of claims

20%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 113 $1,874
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $394
Morphine Sulfate Er Morphine Sulfate Brand 14 $197
Tizanidine Hcl Generic 17 $191
Gabapentin Generic 16 $179
Clindamycin Hcl Generic 62 $116

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$181,446

Of which drugs: $105

Medicare patients

165

Average age 70

Services billed

2,640

119 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 42%
Depression 35%
Chronic kidney disease 25%
Ischemic heart disease 21%
COPD 20%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 33 710 $63

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

677 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record